Literature DB >> 22561131

Awakening properties of newly discovered highly selective H₃ receptor antagonists in rats.

Guy Griebel1, Michel Decobert, Agnès Jacquet, Sandra Beeské.   

Abstract

The objective of the present study was to compare the awakening effects of two newly discovered H₃ receptor antagonists (i.e. SAR110894 and SAR110068) with those of reference H₃ receptor ligands (i.e. ciproxifan, ABT-0239 and GSK189254) and classical psychostimulants (i.e. amphetamine and modafinil) by using EEG recording in rats during their light phase. Results showed that SAR110068 (10 and 30 mg/kg, p.o.) increased wakefulness and decreased slow wave sleep to a similar degree than ciproxifan (10 mg/kg, i.p.), ABT-0239 (10 mg/kg, p.o.) and GSK189254 (10 mg/kg, p.o.), while SAR110894 (3-30 mg/kg, p.o.) did not modify significantly any of the sleep/wakefulness parameters. Time-course analysis revealed that the awakening effects of GSK189254 lasted for about 1h, while ciproxifan, ABT-0239 and SAR110068 produced such effects for 3-4 h. The magnitude of the awakening effects of the psychostimulants, amphetamine (3 mg/kg, i.p.) and modafinil (300 mg/kg, i.p.), was dramatically higher than with the H₃ compounds, and they lasted for 5 and 6 h, respectively. However, unlike the H₃ receptor antagonists, both psychostimulants produced a strong increase in theta (θ) rhythm, which is indicative of CNS side effects, such as hyperactivity or abnormal excitation. In conclusion, this study provides further evidence to support the potential use of H₃ receptor antagonists in the treatment of vigilance and sleep-wake disorders such as narcolepsy.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22561131     DOI: 10.1016/j.bbr.2012.04.033

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  4 in total

Review 1.  Therapeutic Potential of Histamine H3 Receptors in Substance Use Disorders.

Authors:  Patricia Di Ciano; Christian S Hendershot; Bernard Le Foll
Journal:  Curr Top Behav Neurosci       Date:  2022

2.  Loss of Melanopsin Photoreception and Antagonism of the Histamine H3 Receptor by Ciproxifan Inhibit Light-Induced Sleep in Mice.

Authors:  Fanuel Muindi; Damien Colas; Jesse Ikeme; Norman F Ruby; H Craig Heller
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

3.  Possible use of a H3R antagonist for the management of nonmotor symptoms in the Q175 mouse model of Huntington's disease.

Authors:  Daniel S Whittaker; Huei-Bin Wang; Dawn H Loh; Roger Cachope; Christopher S Colwell
Journal:  Pharmacol Res Perspect       Date:  2017-10

Review 4.  Sites of action of sleep and wake drugs: insights from model organisms.

Authors:  Jason Rihel; Alexander F Schier
Journal:  Curr Opin Neurobiol       Date:  2013-05-23       Impact factor: 6.627

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.